EMEA-001084-PIP01-10
Key facts
| Invented name |
Exelon
|
| Active substance |
rivastigmine
|
| Therapeutic area |
Neurology
|
| Decision number |
P/65/2011
|
| PIP number |
EMEA-001084-PIP01-10
|
| Pharmaceutical form(s) |
Transdermal patch
|
| Condition(s) / indication(s) |
Treatment of dementia
|
| Route(s) of administration |
Transdermal use
|
| Contact for public enquiries |
Novartis Europharm Ltd
E-mail: paediatric.enquiries@novartis.com
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|